Simplified pharmacoeconomics of critical care and severe sepsis

Journal of Intensive Care Medicine

Volumn 22, Issue 5, 2007, Pages 283-293

  Ernst, Frank R ^a,b   Levy, Howard ^a   Qualy, Rebecca L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Premier Research   (United States)

Author keywords

Cost effectiveness; Critical care; Drotrecogin alfa (activated); Pharmacoeconomics; Severe sepsis

Indexed keywords

DROTRECOGIN;

CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INTENSIVE CARE; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SEPSIS;

ANTI-INFECTIVE AGENTS; COST-BENEFIT ANALYSIS; CRITICAL CARE; DECISION SUPPORT TECHNIQUES; ECONOMICS, PHARMACEUTICAL; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; TERMINOLOGY AS TOPIC; UNITED STATES;

EID: 36749042693     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066607304231     Document Type: Review

References (65)

1. Values, Ethics & Rationing In Critical Care (VERICC) Task Force. Poll Reveals Bedside Rationing Practices. http://www.vericc.org/03_rationing/ sccm_poll.htm. Accessed September 15, 2005.
2. Society of Critical Care Medicine. Critical Care Units: A Descriptive Analysis. 1 st ed. Des Plaines, IL: Society of Critical Care Medicine ; 2005.
3. Drummond MF, O'Brien B, Stoddart GL, et al, eds. Methods for the Economic Evaluation of Health Care Programmes. 2 nd ed. New York, NY: Oxford University Press ; 1997.
4. Bootman JL, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics. 3 rd ed. Cincinnati, OH: Harvey Whitney Books ; 2005.
5. Townsend RJ Postmarketing drug research and development. Drug Intelligence and Clinical Pharmacy. 1987 ; 21: 134-136.
6. Center on the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry. Boston, MA: Tufts-New England Medical Center, ICRHPS. http://www.tuftsnemc.org/cearegistry. Accessed July 11, 2006.
7. Johnson JA, Bootman JL Drug-related morbidity and mortality: a cost-of illness model. Arch Int Med. 1995 ; 155: 1949-1956.
8. Ernst FR, Grizzle AJ Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash DC). 2001 ; 41: 192-199.
9. International Society for Pharmacoeconomics and Outcomes Research. Proceedings of the Advisory Panel Meeting and Conference on Pharmacoeconomic Issues. Value Health. 1999 ;2: 67-112.
10. Drummond M., Brown R., Fendrick AM, et al. Use of pharmacoeconomics information-report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health. 2003 ; 6: 407-416.
11. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine: Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276: 1172-1177.
12. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276: 1253-1258.
13. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. JAMA. 1996 ; 276: 1339-1341.
14. Angus DC, Rubenfeld GD, Roberts MS, et al. Understanding cost-effectiveness in critical care: report from the Second American Thoracic Society Workshop on Outcomes Research. Am J Respir Crit Care Med. 2002 ; 165: 540-550.
15. Angus DC, Linde-Zwirble WT, Clermont G., et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003 ; 31: 1-11.
16. Coughlin MT, Angus DC Economic evaluation of new therapies in critical illness. Crit Care Med. 2003 ; 31 (1 suppl). S7 - S16.
17. Frampton JE, Foster RH Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis. Pharmacoeconomics. 2004 ; 22: 445-476.
18. Burchardi H., Schneider H. Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics. 2004 ; 22: 793-813.
19. Wood KA, Angus DC Pharmacoeconomic implications of new therapies in sepsis. Pharmacoeconomics. 2004 ; 22: 895-906.
20. Davies A., Ridley S., Hutton J., et al. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia. 2005 ; 60: 155-162.
21. Wen L., Badgett R., Cornell J. Number needed to treat: a descriptor for weighing therapeutic options. Am J Health Syst Pharm. 2005 ; 62: 2031-2036. doi 10.2146/ajhp040558.
22. Kravitz RL, Duan N., Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004 ; 82: 661-687.
23. Heyland DK, Gafni A., Kernerman P., et al. How to use the results of an economic evaluation. Crit Care Med. 1999 ; 27: 1195-1202.
24. Rice DP Estimating the cost of illness. Health Economics Series No. 6, PHS No. 947-6. Washington, DC: US Government Printing Office ; 1966.
25. Rice DP Cost-of-illness studies: fact or fiction? Lancet. 1994 ; 344: 1519-1520.
26. Shiell A., Gerard K., Donaldson C. Cost of illness studies: an aid to decision making? Health Policy. 1987 ; 8: 317-323.
27. Behrens C., Henke KD Cost of illness studies: no aid to decision making? Reply to Shiell. Health Policy. 1988 ; 10: 137-141.
28. Hodgson TA Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al. Health Policy. 1988 ; 11: 57-60.
29. Hilleman DE, Mohiuddin SM, Lucas BD Jr, et al. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther. 1994 ; 16: 88-102.
30. Rancourt C., Grégoire JP, Simons WR, et al. Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years. Pharmacoeconomics. 2003 ; 21: 429-442.
31. Hopley C., Salkeld G., Wang JJ, et al. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol. 2004 ; 88: 450-454.
32. Ellstrom M., Ferraz-Nunes J., Hahlin M., et al. A randomized trial with a cost-consequence analysis after laparoscopic and abdominal hysterectomy. Obstet Gynecol. 1998 ; 91: 30-34.
33. Gold MR, Siegel JE, Russell LB, et al, eds. Cost effectiveness in Health and Medicine. New York, NY: Oxford University Press ; 1996.
34. Warner KE, Luce BR Cost-Benefit and Cost-Effectiveness Analysis in Health Care: Principles, Practice, and Potential. Ann Arbor, MI: Health Administration Press ; 1982.
35. Dellinger RP, Carlet JM, Masur H.,, et al. for the Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004 ; 32: 858-873.
36. Gao F., Melody T., Daniels DF, et al. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study. Crit Care. 2005 ; 9: R764 - R770. doi:10.1186/ cc3909.
37. Mark DB Economic analysis methods and endpoints. In: Califf RM, Mark DB, Wagner GS, eds. Acute Coronary Care in the Thrombolytic Era. 2nd ed. St. Louis, MO: Mosby-Year Book ; 1995: 167-182.
38. Laufer FN The $50,000 question- whose threshold is it [editorial]? Society for Medical Decision Making Newsletter. 2005 ; 17: 7.
39. Laufer FN Thresholds in cost-effectiveness analysis-more of the story [letter]. Value Health. 2005 ; 8: 86.
40. Laupacis A., Feeny D., Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992 ; 146: 473-481.
41. Hibbert CL, Coates EJ Methodological issues in studies reporting the costs of sepsis patients. Care of the Critically Ill. 2004 ; 20 (6). 167-176.
42. Neumann PJ Why don't Americans use cost-effectiveness analysis? Am J Manag Care. 2004 ; 10 (5). 308-312.
43. Tunis SR Economic analysis in healthcare decisions. Am J Manag Care. 2004 ; 10 (5). 301-304.
44. Henry DA, Hill SR, Harris A. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA. 2005 ; 294: 2630-2632.
45. Bergthold LA, Singer SS, Huang A., et al. Using evidence and cost in managed care decision-making (Stanford, CA: Center for Health Policy / Center for Primary Care and Outcomes Research, Stanford University, 2002). http://content.healthaffairs.org/cgi/data/hlthaff.w4.284v1/DC2/1. Accessed July 11, 2006.
46. Pearson SD, Rawlins MD Quality, innovation, and value for money: NICE and the British National Health Service. JAMA. 2005 ; 294: 2618-2622.
47. Medicare Prescription Drug Improvement and Modernization Act of 2003. Pub L 108-173. http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname= 108_cong_public_laws&docid=f:publ173.108.pdf. Accessed July 11, 2006.
48. Taylor RS, Drummond MF, Salkeld G., et al. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. 2004 ; 329: 972-975. doi:10.1136/bmj.329.7472.972.
49. Hamel MB, Phillips RS, Davis RB, et al. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med. 2000 ; 109: 614-620.
50. Manns BJ, Lee H., Doig CJ, et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med. 2002 ; 347: 993-1000.
51. Neilson AR, Burchardi H., Chinn C., et al. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care. 2003 ; 18: 217-227.
52. Riou França L., Launois R., Le Lay K., et al. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis with multiple organ failure. Int J Technol Assess Health Care. 2006 ; 22: 101-108.
53. Sacristan JA, Prieto L., Huete T., et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis in Spain [Spanish]. Gac Sanit. 2004 ; 18: 50-57.
54. Lucioni C., Guidi L., Mazzi S., et al. The treatment of sepsis patients with drotrecogin alfa (activated): an economic evaluation with reference to Italy [abstract]. Value Health. 2002 ; 5: 562.
55. Hjelmgren J., Persson U., Tennvall GR Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden. Am J Ther. 2005 ; 12: 425-430.
56. Technology Appraisal Guidance 84: Drotrecogin alfa (activated) for severe sepsis. London: National Institute for Clinical Excellence ; 2004. http://www.nice.org.uk/TA084guidance. Accessed July 11, 2006.
57. Green C., Dinnes J., Takeda A., et al. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris®) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technol Assess. 2005 ; 9 ( 11 ).
58. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis. 1995 ; 15 (3). 369-390.
59. National Highway Traffic Safety Administration, Department of Transportation. Federal motor vehicle standards; tires; final rule. Fed Regist. 2003 ; 68 (123). 38115-38152.
60. Sanders GD, Hlatky MA, Owens DK Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005 ; 353: 1471-1480.
61. Angus DC, Linde-Zwirble WT, Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 ; 29: 1303-1310.
62. Samsa GP, Matchar DB, Harnett J., et al. A cost-minimization analysis comparing azithromycin-based and levofloxacinbased protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial. Chest. 2005 ; 128: 3246-3254.
63. Chaix C., Durand-Zaleski I., Alberti C., et al. Control of endemic methicillin-resistant staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA. 1999 ; 282: 1745-1751.
64. Graf J., Wagner J., Graf C., et al. Five-year survival, quality of life, and individual costs of 303 consecutive medical intensive care patients-a cost-utility analysis. Crit Care Med. 2005 ; 33: 547-555.
65. Annemans L., Minjoulat-Rey MC, DeKnock M., et al. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium. Acta Clin Belg. 2004 ; 59: 346-357.